Abstract
Localized prostate cancer is characterized by marked biological heterogeneity, creating a therapeutic dilemma in which the reduction of progression and metastatic risk must be weighed against treatment-related morbidity and long-term quality of life. This narrative review critically compares active surveillance with radical prostatectomy and radiotherapy in men with localized disease, emphasizing oncological outcomes, selection criteria, functional consequences, and shared decision-making. A structured literature search was conducted in 2026 using PubMed/MEDLINE and current European Association of Urology and American Urological Association/American Society for Radiation Oncology guidance. Randomized trials, long-term active-surveillance cohorts, prospective patient-reported outcome studies, systematic reviews, and contemporary observational evidence were prioritized. Long-term randomized evidence shows very low prostate-cancer-specific mortality across monitoring, surgery, and radiotherapy in predominantly PSA-detected localized disease, but conservative management is associated with more progression and metastases. Modern protocol-directed active surveillance, however, differs from older PSA-triggered monitoring by incorporating magnetic resonance imaging, repeat biopsy, and risk reclassification, and contemporary cohorts report low 10-year rates of metastasis and prostate-cancer mortality in appropriately selected patients. Quality-of-life profiles differ substantially by strategy: radical prostatectomy produces the greatest early and persistent burden of urinary incontinence and sexual dysfunction, whereas radiotherapy more often causes bowel symptoms and irritative urinary effects, with additional hormonal toxicity when androgen-deprivation therapy is used. Active surveillance preserves baseline function initially but requires repeated testing and carries the psychological and clinical burden of living with untreated cancer. The optimal approach is therefore risk-adapted rather than uniformly conservative or radical. Active surveillance is the standard strategy for most men with low-risk disease and selected favorable intermediate-risk disease, while radical treatment remains appropriate when tumor biology, extent, life expectancy, patient preference, or evidence of progression shifts the balance toward definitive local control.